However, no relevant mutations or Single Nucleotide Polymorphisms (SNPs) affecting the aberrant expression of SLC22A17 in cancer have been described, nor the epigenetic alterations associated with SLC22A17 dysregulation in cancer. This evidence concerns the gene SLC22A17 and cancer.